Related Experiment Videos
[Treatment of euthyroid goiter in the elderly]
N Imbrogno1, G De Angelis, A Salandri
1Cattedra di Endocrinologia, Università di Roma La Sapienza, Roma, Italia.
La Clinica Terapeutica
|December 1, 2001
Summary
Levothyroxine (L-T4) therapy shows limited effectiveness in reducing thyroid nodule size or number in elderly patients with multinodular goiter. It also does not aid in weight reduction for obese individuals.
Area of Science:
- Endocrinology
- Geriatric Medicine
- Thyroidology
Context:
- Multinodular goiter is common in the elderly.
- Levothyroxine (L-T4) is a synthetic thyroid hormone used for treatment.
- Obesity is a prevalent comorbidity in the elderly population.
Purpose:
- To evaluate the efficacy of levothyroxine (L-T4) therapy.
- To assess its impact on nodule characteristics and body weight.
- In elderly individuals with multinodular euthyroid goiter.
Summary:
- Levothyroxine (L-T4) therapy was administered to 187 elderly patients (63-85 years) with multinodular euthyroid goiter.
- No significant changes in nodule size or number were observed in 82% of patients, regardless of weight.
- Obese patients did not experience significant weight reduction with L-T4 therapy.
Impact:
- Levothyroxine (L-T4) demonstrates limited effectiveness in reducing thyroid nodule volume or number.
- The therapy may still be useful in preventing the progression of thyroid nodular disease.
- Levothyroxine (L-T4) is ineffective for weight reduction in obese patients with goiter.